Legislation Search

H.R. 5415: Nitazene Control Act of 2025

This bill, titled the Nitazene Control Act of 2025, aims to amend the Controlled Substances Act by permanently classifying a group of synthetic opioids known as nitazenes as Schedule I controlled substances. Here’s a breakdown of what this would entail:

Background and Purpose

The bill recognizes that:

Nitazenes are a class of synthetic opioids, first synthesized in the 1950s, that are extremely potent at the mu-opioid receptor. Some nitazenes can be more potent than fentanyl.
The Drug Enforcement Administration (DEA) has already temporarily or permanently scheduled several nitazene compounds due to their high potential for abuse and lack of accepted medical use.
These substances are increasingly found in the illegal drug market, contributing to overdose incidents and fatal poisonings in the United States.
A permanent classification of nitazenes is viewed as necessary to prevent the emergence of new analogs, facilitate law enforcement efforts, and protect public health.
There are existing pathways created by the HALT Fentanyl Act for research using Schedule I substances, which would still apply to nitazenes.

Permanently Scheduling Nitazenes

The bill specifically adds nitazenes, along with their various forms—such as isomers, esters, ethers, and salts—to the permanent Schedule I list in the Controlled Substances Act. The specific characteristics of these substances include:

Structural modifications that substitute different groups in specific positions of their chemical structure.
Agonist activity at the mu-opioid receptor, which is a property that contributes to their potency as opioids.
Examples of nitazenes included are etonitazene, clonitazene, and metonitazene, among others.

Removal of Temporary Status

Any nitazene compounds that were temporarily scheduled under previous legislation will automatically be considered permanently scheduled upon the enactment of this bill. This means that these substances will be subject to the regulations and restrictions that apply to Schedule I drugs, including stringent regulatory oversight.

Restrictions on Research

The bill clarifies that the amendments made do not authorize new research using these substances without proper registration and compliance with the scheduling requirements. Researchers wishing to study nitazenes will have to navigate existing regulations associated with Schedule I substances.

Relevant Companies

None found.

This is an AI-generated summary of the bill text. There may be mistakes.

Actions

2 actions

Date	Action
Sep. 16, 2025	Introduced in House
Sep. 16, 2025	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Corporate Lobbying

0 companies lobbying